Latest News and Press Releases

IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer

Agreement Focuses on Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and...

– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven...

Interim Data to be Presented for RMC-6236 (RASMULTI(ON) Inhibitor) and RMC-6291 (RASG12C(ON) Inhibitor) Company to Host Investor Webcast Following ESMO Data Presentation on October 22 at 12:30 p.m....

FLORHAM PARK, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...

MONTRÉAL, 12 oct. 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou « la Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au...

MONTREAL, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...

HOUSTON, June 16, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. (Invectys), The University of Texas MD Anderson Cancer Center and the Cell Therapy Manufacturing Center (CTMC), a joint venture between...

CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Contrast agents used in MRI scans to improve the clarity of imaging for diagnostic accuracy, accumulate in the brain and body of every patient,...

PASADENA, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced that the National Cancer Institute (NCI) has resumed enrolling patients into their...